Drug Prices
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in the program’s price negotiations, the Centers for Medicare & Medicaid Services announced.
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar products.
A new Centers for Medicare…
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation Reduction Act designed to reduce health care costs.
A new plan will transition Blue Shield of California’s drug supply management from CVS Health’s PBM to five companies — a move the payer believes will save its 4.8 million members as much as $500 million a year in drug costs or about 10% to 15% of what it spends on drugs annually.
A new study by Business Group on Health reveals that, amid increases in the percentage of health care dollars spent on pharmacy, 92% of employers are concerned about high-cost drugs in the pipeline, with 91% reporting concern about pharmacy cost trends overall.
The Centers for Medicare & Medicaid Services June 30 released revised guidance detailing how it will implement an Inflation Reduction Act program to negotiate Medicare prices with makers of certain high-cost, single-source drug and biological products in 2023 and 2024 for prices effective in 2026.
Broadlawns Medical Center of Des Moines treats a diverse population of patients, addressing the medical, societal, and behavioral health needs of local citizens – from the greater Des Moines area – serving more than 72,757 patients in fiscal year 2022.
A new AHIP report makes baseless claims that hospitals drive up specialty drug costs when in fact insurance companies drive up profits by steering patients to their own specialty pharmacies, write AHA’s Mark Howell, director of policy and patient safety, and Bharath Krishnamurthy, director of…
A new AHIP “report” suggests that hospitals are significantly marking up the costs of drugs to the detriment of patients. They make baseless claims that specialty pharmacies, many of which insurers conveniently own through their pharmacy benefit manager (PBM) affiliates, provide a lower-cost…